United States of America
Research & Development

Driving Innovation

True innovation is best fostered through a healthy mix of of in-house efforts, nimble partnerships, and empowering trustworthy third parties to run with ideas. Bayer’s US R&D team aims to find solutions to global focus areas, and R&D activities are conducted in the US, as well as Germany, Japan, China, Finland and Norway.

 

Medical Innovation in the US

Bayer’s West Coast Innovation Center in San Francisco, California is one of a global network of research hubs and is the center of the company’s pharmaceutical research efforts in the United States. Situated in close proximity to hundreds of life science companies and organizations, Bayer’s West Coast Innovation Center is supporting drug discovery research and development for Bayer in its core therapeutic areas.

 

Partnerships

We fully realize that the knowledge of biochemical processes and underlying genetic causes of diseases is growing at record speed, and research and development require a degree of specialization that a single organization can no longer achieve on its own. Through partnering we can fully leverage today’s scientific know-how and translate it into innovative medicines for patients.

 

The West Coast Innovation Center in San Francisco plays an important role in establishing partnerships with startups, academic institutions and researchers. Within the same building as the West Coast Innovation Center, Bayer opened the CoLaborator, a unique incubator space for startup companies, further demonstrating the company’s commitment to collaboration as a key component to bringing new therapies to patients.

 

Bayer’s Innovation Center in Boston is a partnering hub located in the heart of the vibrant Cambridge life science community, fostering partnerships that advance the discovery and development of new therapies focused on areas of high medical unmet patient need. Bayer is currently is collaborating with leading local organizations such as the Broad Institute of MIT and Harvard.

 

In addition, Bayer partnered with CRISPR Therapeutics to form Casebia Therapeutics, a novel joint venture focused on discovering, developing and commercializing new CRISPR/Cas9-based breakthrough therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease, blindness, hearing loss, and heart disease.

 

Innovative Biologics Manufacturing

Bayer has a significant biologics manufacturing operation in Berkeley, CA with over 1,500 employees. The Berkeley site functions as the headquarters for Bayer’s biotechnology product supply organization, as well as the global manufacturing center for Bayer hemophilia therapies.

 

Therapeutic protein manufacturing is one of the most complex manufacturing processes, and Bayer is committed to researching and developing, innovative, cost-effective, environmentally safe, and state-of-the-art manufacturing processes for new protein products in the Bayer pipeline.